Clinical Issues in Rheumatoid Arthritis
The Evolving Role of JAK Inhibitors
Meeting Slides
Guidelines
2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis.
Singh JA, et al. Arthritis Rheumatol. 2016;68(1):1-26.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
Smolen JS, et al. Ann Rheum Dis. 2017;76(6):960-977.
Patient, Caregiver, and Provider Resources
American College of Rheumatology: Patient and Caregiver Resources
The ACR has produced a library of videos about the impact of rheumatic disease, what to do when diagnosed with rheumatic disease, when to see a rheumatologist, and what patients have to say about their experiences of living with rheumatic disease.
Arthritis Foundation
The Arthritis Foundation provides self-care tools and resources covering treatment options, pain management, diet and exercise, and common comorbidities associated with many different arthritic conditions.
European League Against Rheumatism
EULAR is an organization that represents people with arthritis/rheumatism, health professionals, and scientific societies of rheumatology of all the European nations.
NIH Health Topics: Rheumatoid Arthritis
A resource from the National Institute of Arthritis and Musculoskeletal and Skin Diseases for people who have rheumatoid arthritis, as well as for their family members, friends, and others who want to find out more about rheumatoid arthritis.
Suggested Readings
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.
Schwartz DM, et al. Nat Rev Drug Discov. 2017;17(1):78.
Clinical efficacy of new JAK inhibitors under development. Just more of the same?
Westhovens R.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomized controlled trial.
Fleischmann R, et al. Lancet. 2017;390(10093):457-468.
Baricitinib versus placebo or adalimumab in rheumatoid arthritis.
Taylor PC, et al. N Engl J Med. 2017;376(7):652-662.
Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease‐modifying antirheumatic drug treatment.
Fleischmann R, et al. Arthritis Rheumatol. 2017;69(3):506-517.
A phase 3, randomized, controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-naïve patients with active rheumatoid arthritis.
van Vollenhoven R, et al. Arthritis Rheumatol. 2018;70(suppl 10). Abstract 891.
A phase 3, randomized, double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate.
Fleischmann R, et al. Arthritis Rheumatol. 2018;70 (suppl 10). Abstract 890.
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the select phase 3 clinical program.
Cohen SB, et al. Ann Rheum Dis. 2019;78(suppl 2):A357. Abstract THU0167.
Safety and efficacy of filgotinib in a phase 3 trial of patients with active rheumatoid arthritis and inadequate response or intolerance to biologic DMARDs.
Genovese MC, et al. Arthritis Rheumatol. 2018;70(suppl 10). Abstract L06.
Thromboembolism with Janus kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk?
Scott IC, et al. Drug Saf. 2018;41(7):645-653.
Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis.
Clowse ME, et al. Drug Saf. 2016;39(8):755-762.
Additional abstracts from the European Congress of Rheumatology 2019 Meeting.
June 2019; Madrid, Spain.
Relevant Resources
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Evolving Strategies for Diagnosis and Long-Term Management
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Targeting Immune Dysregulation and Delivering Comprehensive Care
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Debates & Discussions on the Evolving Role of JAK Inhibitors
Unpacking the Evidence for Their Use Today and Tomorrow
Unlocking Novel Paths to Patient Care
The Increasing Role of JAK Inhibitors
Unlocking Novel Paths to Patient Care
New Pathways to Patient Management
A Focus on Clinical Evidence and Guideline Recommendations
New Avenues to the Management of Severe Asthma
Getting on the Fast Track to Identify AxSpA
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Finding the Path in Chronic Rhinosinusitis with Nasal Polyps
From Patient Evaluations to New Targeted Therapies
